This is a U.S. news story, published by Yahoo, that relates primarily to The European Medicines Agency's news.
For more U.S. news, you can click here:
more U.S. newsFor more biology news, you can click here:
more biology newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
cancer cell therapies. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest blood cancers news, cell therapies news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Pharmacovigilance Risk Assessment CommitteeReuters
•77% Informative
Makers of cancer cell therapies known as CAR-T treatments will need to highlight the risk of secondary blood cancers in patients who use them.
The European Medicines Agency's mandate comes at the end of a five-month safety review.
The U.S. health regulator in April imposed its strongest "boxed warning" on the treatments for secondary cancers.
VR Score
88
Informative language
96
Neutral language
18
Article tone
formal
Language
English
Language complexity
63
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links